Futura Medical study results signals the potential of its lead treatment
The company is developing MED2005, a fast-acting gel for men who suffer erectile dysfunction
Company
Futura Medical PLC
LON:FUM
Futura Medical specialises in the development and global commercialisation of innovative sexual health products, including lead product Eroxon®. The company's core strength lies in its research, development and commercialisation of topically delivered gel formulations in sexual health products.
305 stories · page 10 of 16
Archive
Proactive news snapshot: i3 Energy, Concepta, Horizonte Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Serica Energy rises on regulatory green light, but PhotonStar LED Group shares fall sharply
A look at some of the big winners and losers in the UK equity market on Wednesday
Futura Medical passes major milestone as it doses first patient in phase III study
MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis
Investments and investor services
FTSE 100 closes firmly ahead as it puts dismal October to rest
The FTSE 100 closed up around 92 points at 7,182. FTSE 250 also gained..
Essentra dips after mixed trading update, Dechra Pharma trots up on acquisition news
A look at some winners and losers in UK equity trading during Friday's session
Archive
Proactive news snapshot: Hemogenyx Pharmaceuticals, PhotonStar LED, Futura Medical …
A glance at some of the day's highlights from the Proactive Investors newswire
Futura Medical raises funds to finance its erectile dysfunction gel through Phase 3 studies
Three directors have subscribed for shares. Two independent directors have consulted with Futura's nomad and deemed that the terms of the participating directors' participation in the subscription are "fair and reasonable"
FTSE 100 closes ahead as US earnings season gets off to strong start
The UK blue-chip index closed up almost 23 points at 7,049 - up around 0.77% on the week as a whole
Archive
Proactive news snapshot: Amryt Pharma, Directa Plus, Live Company...
A glance at some of the day's highlights from the Proactive Investors newswire
"Excellent" first half for Futura Medical as first dosing in final stage trial of its ED gel draws near
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Investments and investor services
FTSE 100 closes near flat as traders sit on hands ahead of Fed
The UK blue-chip index closed nearly four points higher at 7,511
Archive
Expected US interest rate hike to draw the attention Wednesday, as Trump trade wars rumble on
Aside from the US interest rate decision, corporate updates are due from online fashion retailer Boohoo Group, outsourcer MITIE, and automotive services firm The AA ...
Archive
US interest rate hike eyed, as retailers, tour operators and utilities provide updates in coming week
Aside from the latest Federal Reserve policy meeting, the week ahead will bring updates from the likes of Next, Thomas Cook, TUI, United Utilities, and Pennon
Archive
Proactive news snapshot: Pan African Resources, Strategic Minerals, Strategic Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Mission Marketing Group shares step up, United Carpets declines
A look at some of the biggest risers and fallers in the UK market on Wednesday
Futura Medical begins Phase III trial for erectile dysfunction treatment as erectogenic condom receives shelf-life approval
The pharmaceuticals firm said that the MED2002 trial would involve 1,000 patients with headline data expected by the end of 2019
Investments and investor services
FTSE 100 closes higher as trade fears ebb; Kingfisher leads the laggards
The FTSE 100 closed nearly 31 points higher at 7,331, while FTSE 250 added over 42 at 20,500
SalvaRx plunges as subsidiary hit with “significant” manufacturing delay
A look at some of the biggest risers and fallers in London on Monday
Archive
Proactive news snapshot: Instem, Futura Medical, Kromek Group …
A glance at some of the day's highlights from the Proactive Investors newswire